Aptamer-conjugated graphene oxide-based surface assisted laser desorption ionization mass spectrometry for selective extraction and detection of Aβ1–42 in an Alzheimer’s disease SH-SY5 cell model

Song, Gongshuai; Shui, Ruofan; Wang, Danli; Fang, Ruosi; Yuan, Tinglan; Li, Ling; Feng, Jia; Gao, Feng; Shen, Qing; Gong, Jinyan; Zheng, Fang; Zhang, Manman

doi:10.3389/fnagi.2022.993281

Cited by 6 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to Tau, Takahashi, and colleagues [ 85 ] and Song group [ 86 ] successfully selected RNA aptamers against the Aβ1-40 peptide, showing that the aptamers efficiently inhibit Aβ aggregation in vitro with therapeutic potential for treating AD. More recently, Lida et al focused on preventing AD by destroying the formation of prion protein-Aβ oligomers [ 102 ].…”

Section: Aptamers Targeting Neuro-medically Relevant Targetsmentioning

confidence: 99%

Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development

Wang,

Kobeissy,

Golpich

et al. 2024

Molecules

View full text Add to dashboard Cite

Aptamers developed using in vitro Systematic Evolution of Ligands by Exponential Enrichment (SELEX) technology are single-stranded nucleic acids 10–100 nucleotides in length. Their targets, often with specificity and high affinity, range from ions and small molecules to proteins and other biological molecules as well as larger systems, including cells, tissues, and animals. Aptamers often rival conventional antibodies with improved performance, due to aptamers’ unique biophysical and biochemical properties, including small size, synthetic accessibility, facile modification, low production cost, and low immunogenicity. Therefore, there is sustained interest in engineering and adapting aptamers for many applications, including diagnostics and therapeutics. Recently, aptamers have shown promise as early diagnostic biomarkers and in precision medicine for neurodegenerative and neurological diseases. Here, we critically review neuro-targeting aptamers and their potential applications in neuroscience research, neuro-diagnostics, and neuro-medicine. We also discuss challenges that must be overcome, including delivery across the blood–brain barrier, increased affinity, and improved in vivo stability and in vivo pharmacokinetic properties.

show abstract

Section: Aptamers Targeting Neuro-medically Relevant Targetsmentioning

confidence: 99%

Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development

Wang,

Kobeissy,

Golpich

et al. 2024

Molecules

View full text Add to dashboard Cite

show abstract

“…Bonanni et al (2012) first examined the ability of GO to conjugate with DNA hybrids and discovered its promising role in DNA labeling. Song et al (2022) conjugated GO with Aβ 1-42 -specific aptamer to generate a novel biosensor that could detect Aβ 1-42 of 0.1 to 10 uM through surface-assisted laser desorption ionization mass spectrometry. MiRNA-137 was identified as a reliable biomarker for AD (Azimzadeh et al, 2017).…”

Section: Drug Delivery and Graphene Treatment For Neurological Diseasesmentioning

confidence: 99%

The mechanical, optical, and thermal properties of graphene influencing its pre-clinical use in treating neurological diseases

Yang

Bai

et al. 2023

Front. Neurosci.

View full text Add to dashboard Cite

Rapid progress in nanotechnology has advanced fundamental neuroscience and innovative treatment using combined diagnostic and therapeutic applications. The atomic scale tunability of nanomaterials, which can interact with biological systems, has attracted interest in emerging multidisciplinary fields. Graphene, a two-dimensional nanocarbon, has gained increasing attention in neuroscience due to its unique honeycomb structure and functional properties. Hydrophobic planar sheets of graphene can be effectively loaded with aromatic molecules to produce a defect-free and stable dispersion. The optical and thermal properties of graphene make it suitable for biosensing and bioimaging applications. In addition, graphene and its derivatives functionalized with tailored bioactive molecules can cross the blood–brain barrier for drug delivery, substantially improving their biological property. Therefore, graphene-based materials have promising potential for possible application in neuroscience. Herein, we aimed to summarize the important properties of graphene materials required for their application in neuroscience, the interaction between graphene-based materials and various cells in the central and peripheral nervous systems, and their potential clinical applications in recording electrodes, drug delivery, treatment, and as nerve scaffolds for neurological diseases. Finally, we offer insights into the prospects and limitations to aid graphene development in neuroscience research and nanotherapeutics that can be used clinically.

show abstract

Nanomaterials for sample preparation: An overview of recent innovative strategies

Aguilera,

Safe,

Neyertz

et al. 2024

Reference Module in Chemistry, Molecular Sciences and Chemical Engineering

View full text Add to dashboard Cite

Aptamer-conjugated graphene oxide-based surface assisted laser desorption ionization mass spectrometry for selective extraction and detection of Aβ1–42 in an Alzheimer’s disease SH-SY5 cell model

Cited by 6 publications

References 29 publications

Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development

Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development

The mechanical, optical, and thermal properties of graphene influencing its pre-clinical use in treating neurological diseases

Nanomaterials for sample preparation: An overview of recent innovative strategies

Contact Info

Product

Resources

About